TCR2 Therapeutics to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel in Mesothelin-Expressing Solid Tumors

Rhea-AI Summary

TCR² Therapeutics Inc. (TCRR) announced a conference call on September 17, 2021, to discuss extended data from its ongoing Phase 1 clinical trial of gavo-cel for mesothelin-expressing solid tumors. This data, to be presented at the European Society for Medical Oncology Congress, involves 17 evaluable patients and focuses on three cancer types: malignant mesothelioma, ovarian cancer, and cholangiocarcinoma. The event will include clinical and translational insights, and a replay will be available on their website for 30 days post-event.

Positive

• The conference call will present extended clinical data from 17 evaluable patients, indicating progress in the ongoing clinical trial.
• The Phase 1/2 trial includes multiple indications for gavo-cel, highlighting potential treatment options for patients with solid tumors.

Negative

• None.

CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the Company will host a conference call and live audio webcast on Friday, September 17, 2021 at 9:00am E.T. to discuss extended data from the ongoing Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors.

The dataset will be an extension of the oral presentation at the European Society for Medical Oncology (ESMO) Congress 2021 on September 17 at 14:20 CEST (8:20am ET) (Presentation #959O) that is part of the official ESMO Press Programme. The Company presentation will include clinical and translational data from at least 17 evaluable patients with gavo-cel up to dose level 5 (DL5) in three mesothelin-expressing solid tumor indications: malignant mesothelioma, ovarian cancer and cholangiocarcinoma.

In order to participate in the conference call, please dial 866-220-8062 (domestic) or 470-495-9169 (international) and refer to confirmation number 1597681. The webcast and presentation will be made available on the TCR² Therapeutics website in the Investors section under Events at investors.tcr2.com/events. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.

About TCR² Therapeutics

TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from cancer. TCR²’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC^®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company’s lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR², please visit www.tcr2.com.

Investor and Media Contact:

Carl Mauch
Director, Investor Relations and Corporate Communications
TCR² Therapeutics Inc.
(617) 949-5667
carl.mauch@tcr2.com

FAQ

What is the purpose of the TCRR conference call on September 17, 2021?

The conference call aims to discuss extended data from the Phase 1 clinical trial of gavo-cel targeting mesothelin-expressing solid tumors.

What data will be presented at the ESMO Congress regarding TCRR?

Clinical and translational data involving 17 evaluable patients with gavo-cel will be presented, focusing on three types of cancers.

What types of cancer are being targeted in TCRR's gavo-cel trial?

The gavo-cel trial targets malignant mesothelioma, ovarian cancer, and cholangiocarcinoma.

How can I access the TCRR conference call and presentation?

The conference call can be accessed via phone or through a webcast available on the TCR² Therapeutics website.

When will the TCRR presentation replay be available?

The replay of the presentation will be available on the TCR² Therapeutics website for approximately 30 days after the event.